We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Rising power consumption and costs related to continuous growth in data are bringing data centers face to face with the challenges of delivering greater storage bandwidth and capacity. Marvell’s move to bring its Fibre Channel and Ethernet adapters into vSphere 7.0 aims to meet the evolving requirements of the data center.
Marvell's QLogic 269x 16GFC and 2700 32GFC Series HBAs deliver low-latency, concurrent FCP and FC-NVMe storage access. Besides, the QLogic 2770 Series HBAs deliver 50% more IOPS. Datacenter operators can now leverage FastLinQ adapters to power Marvell's EBOF architecture, comprising NVMe-oF Ethernet SSD converter controllers, SSD controllers and Prestera Ethernet switches. Moreover, edge-to-cloud data centers can deliver better performance at a lower total cost of ownership by utilizing this architecture.
Notably, growing adoption and improved performance of NVMe are driving digital transformation, the success of which requires a strong and high-performance storage network. Marvell’s NVMe solutions are gaining quick momentum in this environment, as reflected in deals with major companies. In October last year, its QLogic suite of host adapters was chosen to power Hewlett Packard’s (HPE - Free Report) ProLiant and Apollo Gen 10 servers.
Despite significant competition in the Fiber Channel adapter business from Broadcom (AVGO - Free Report) and Cisco (CSCO - Free Report) , Marvell continues to be among the leading suppliers of Fiber Channel adapters, with more than 20 million ports shipped.
Significant demand from storage controller customers in the HDD, SSD and fiber channel end markets is positively impacting revenues from the company’s storage business.
Per Technavio, the global fiber channel adapter market is anticipated to witness a CAGR of more than 14% between 2017 and 2021. This forecast bodes well for the company.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Marvell Integrates Ethernet Adapters Into VMWare vSPhere
Marvell’s (MRVL - Free Report) QLogic Fibre Channel and FastLinQ Ethernet adapter solutions will now enable NVMe over Fabrics (NVMe-oF) technology in VMwarevSphere 7.0, displaying its continued efforts to strengthen its end-to-end Ethernet storage capabilities.
Rising power consumption and costs related to continuous growth in data are bringing data centers face to face with the challenges of delivering greater storage bandwidth and capacity. Marvell’s move to bring its Fibre Channel and Ethernet adapters into vSphere 7.0 aims to meet the evolving requirements of the data center.
Marvell's QLogic 269x 16GFC and 2700 32GFC Series HBAs deliver low-latency, concurrent FCP and FC-NVMe storage access. Besides, the QLogic 2770 Series HBAs deliver 50% more IOPS. Datacenter operators can now leverage FastLinQ adapters to power Marvell's EBOF architecture, comprising NVMe-oF Ethernet SSD converter controllers, SSD controllers and Prestera Ethernet switches. Moreover, edge-to-cloud data centers can deliver better performance at a lower total cost of ownership by utilizing this architecture.
Notably, growing adoption and improved performance of NVMe are driving digital transformation, the success of which requires a strong and high-performance storage network. Marvell’s NVMe solutions are gaining quick momentum in this environment, as reflected in deals with major companies. In October last year, its QLogic suite of host adapters was chosen to power Hewlett Packard’s (HPE - Free Report) ProLiant and Apollo Gen 10 servers.
Marvell Technology Group Ltd. Price and Consensus
Marvell Technology Group Ltd. price-consensus-chart | Marvell Technology Group Ltd. Quote
Fiber Channel Adapters: A Growth Driver
Despite significant competition in the Fiber Channel adapter business from Broadcom (AVGO - Free Report) and Cisco (CSCO - Free Report) , Marvell continues to be among the leading suppliers of Fiber Channel adapters, with more than 20 million ports shipped.
Significant demand from storage controller customers in the HDD, SSD and fiber channel end markets is positively impacting revenues from the company’s storage business.
Per Technavio, the global fiber channel adapter market is anticipated to witness a CAGR of more than 14% between 2017 and 2021. This forecast bodes well for the company.
Marvell currently has a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>